Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Gynecol Oncol. 2010 Oct;119(1):38-42. doi: 10.1016/j.ygyno.2010.05.031. Epub 2010 Jul 6.
To assess the morbidity and mortality associated with extensive upper abdominal surgery (EUAS) performed during primary cytoreduction for advanced ovarian carcinoma.
We identified all patients who underwent EUAS during primary cytoreduction for advanced ovarian, tubal, or peritoneal cancer at our institution from 1/01 to 12/06. Major grade 3-5 complications were those that led to invasive radiologic intervention, re-operation, unplanned ICU admission, chronic disability, or death within 30 days of surgery.
There were 141 eligible patients, with a median age of 60 years (range, 38-82). The majority of patients had stage IIIC disease, 103 (73%); serous histology, 131 (93%); and ascites, 118 (84%). There were 229 EUAS procedures performed-diaphragm peritonectomy, 101 (72%); splenectomy, 45 (32%); full-thickness diaphragm resection, 19 (14%); partial hepatectomy, 18 (13%); distal pancreatectomy, 17 (12%); cholecystectomy, 15 (11%); and resection of porta hepatis tumor, 14 (10%). Cytoreductive outcomes were: no gross residual, 42 (30%); residual ≤ 1cm, 85 (60%); and residual >1cm, 14 (10%). Grade 3-5 complications occurred in 31 (22%) patients, including 2 mortalities (1.4%). In 21/31 (68%), the complication was successfully managed with percutaneous drainage of infected or non-infected collections. Overall median survival for all patients was 57 months.
Rates of major morbidity and mortality following EUAS for primary cytoreduction were 22% and 1.4%, respectively. Approximately two-thirds of complications were readily managed by percutaneous drainage of collections. With an overall median survival of 57 months in a cohort of patients with a large tumor burden, this rate of morbidity and mortality appears acceptable.
评估广泛上腹部手术(EUAS)在原发性细胞减灭术治疗晚期卵巢癌中的发病率和死亡率。
我们在我院 2001 年 1 月至 2006 年 12 月期间,对所有在原发性细胞减灭术治疗晚期卵巢癌、输卵管癌或腹膜癌过程中接受 EUAS 的患者进行了识别。主要的 3-5 级并发症是指导致侵袭性放射学介入、再次手术、计划外 ICU 入院、慢性残疾或术后 30 天内死亡的并发症。
共有 141 名符合条件的患者,中位年龄为 60 岁(范围为 38-82 岁)。大多数患者患有 IIIC 期疾病,103 例(73%);浆液性组织学,131 例(93%);腹水,118 例(84%)。进行了 229 次 EUAS 手术-膈肌腹膜切除术 101 例(72%);脾切除术 45 例(32%);全层膈肌切除术 19 例(14%);部分肝切除术 18 例(13%);胰体尾切除术 17 例(12%);胆囊切除术 15 例(11%);肝门肿瘤切除术 14 例(10%)。细胞减灭术的结果是:无肉眼残留 42 例(30%);残留≤1cm 85 例(60%);残留>1cm 14 例(10%)。31 例(22%)患者发生 3-5 级并发症,包括 2 例死亡(1.4%)。在 21/31 例(68%)患者中,并发症通过经皮引流感染或非感染性积液得到成功处理。所有患者的中位总生存时间为 57 个月。
EUAS 用于原发性细胞减灭术的主要发病率和死亡率分别为 22%和 1.4%。约三分之二的并发症可通过经皮引流积液得到有效处理。在一组具有较大肿瘤负荷的患者中,中位总生存时间为 57 个月,这种发病率和死亡率似乎是可以接受的。